BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37294921)

  • 1. Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS).
    Mytheen S; Varghese A; Joy J; Shaji A; Tom AA
    Expert Opin Drug Saf; 2023; 22(10):985-994. PubMed ID: 37294921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
    Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
    Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
    Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
    Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature.
    Pan C; Cao M; Yan C; Ou X; Zhang X; Xu W; Xu Y; Cui X
    Expert Opin Drug Saf; 2023; 22(6):469-476. PubMed ID: 36794347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.
    Liu T; Gao R; Li L; Wu B; Wu F
    Int J Clin Pharm; 2023 Dec; 45(6):1483-1491. PubMed ID: 37606843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews.
    Song YK; Song J; Kim K; Kwon JW
    Front Pharmacol; 2021; 12():792877. PubMed ID: 35087406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
    Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
    Setyawan J; Azimi N; Strand V; Yarur A; Fridman M
    Drug Saf; 2021 Aug; 44(8):889-897. PubMed ID: 34120321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitor-Tofacitinib associated with pemphigus: an analysis of the FDA adverse event reporting system data.
    Wang L; Zhao B
    Expert Opin Drug Saf; 2023; 22(12):1317-1320. PubMed ID: 37722813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration.
    Qian J; Xue X; Shannon J
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1046-1052. PubMed ID: 36001100
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.
    Goldman A; Galper BL; Druyan A; Grossman C; Sharif K; Shechtman L; Moshkovits Y; Lahat A; Ben-Zvi I
    Semin Arthritis Rheum; 2024 May; 67():152461. PubMed ID: 38772185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.
    Hoisnard L; Lebrun-Vignes B; Maury S; Mahevas M; El Karoui K; Roy L; Zarour A; Michel M; Cohen JL; Amiot A; Claudepierre P; Wolkenstein P; Grimbert P; Sbidian E
    Sci Rep; 2022 May; 12(1):7140. PubMed ID: 35504889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
    Mori S; Ogata F; Tsunoda R
    Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Scott IC; Hider SL; Scott DL
    Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.